Actively Recruiting
Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
Led by Beijing Tiantan Hospital · Updated on 2025-02-18
360
Participants Needed
1
Research Sites
158 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the changes in brain structure and functional networks resulting from cerebral revascularization, as well as their relationship with cognitive improvement.
CONDITIONS
Official Title
Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease.
- Participants must be between 18 and 60 years of age.
- Please sign the informed consent form.
You will not qualify if you...
- Patients with concurrent atherosclerosis, autoimmune diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism that may cause secondary cerebrovascular lesions.
- Individuals younger than 18 years or older than 60 years.
- Those with contraindications for magnetic resonance imaging.
- Patients who are unable to complete cognitive brain assessments.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Tiantan Hospital
Beijing, China, China, 100070
Actively Recruiting
Research Team
Q
Qian Zhang, MD
CONTACT
C
Chaofan Zeng, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here